

# ForPatients

by Roche

## Age-Related Macular Degeneration Geographic Atrophy

### **A study to look at how safe a study medicine was for patients – when taken at different doses - and how this medicine was processed through the body**

Safety and Tolerability Study of RO7171009 in Participants With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD)

**Trial Status**  
Completed

**Trial Runs In**  
1 Countries

**Trial Identifier**  
NCT03295877 GR39821

---

*The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.*

#### ***Trial Summary:***

This Phase 1, open-label, multicenter study will investigate the safety and tolerability of RO7171009 following single and multiple intravitreal (ITV) administrations in patients with GA secondary to AMD. The study consists of two stages: Single Dose-Escalation (SAD) and Multiple-Dose (MD) stages.

**Genentech, Inc.**  
Sponsor

**Phase 1**  
Phase

---

**NCT03295877 GR39821**  
Trial Identifiers

---

#### ***Eligibility Criteria:***

**Gender**  
All

**Age**  
≥ 50 Years

**Healthy Volunteers**  
No

---

This was a study to investigate a new medicine (FHTR2163) in patients with an eye disease, called “age-related macular degeneration with geographic atrophy”, or “AMD with GA”. Patients were injected in their eye with different amounts of the study medicine to find the dose that was safe.